[Treatment of hormonal refractory metastatic prostate cancer].
Hormonal refractory metastatic prostate cancer is a fatal disease with a poor prognosis. Treatment options are palliative with second line anti-hormonal, estrogens and prednisolon. When palliation is the goal, the side effects have to be carefully considered. Local radiotherapy has an effective pain relieving effect, and can be repeated. Chemotherapy with docetaxel and prednisolon is indicated in patients with symptomatic metastatic disease. Newer options with immunotherapy and designed molecules have not yet proven effective. Pain and anemia are significant symptoms and should be treated in a multidisciplinary setting.
Sengeløv
Lisa
L
Herlev Hospital, Onkologisk Afdeling, Herlev. lisa.sengelov@dadlnet.dk
Klarskov
Ole Peter
OP
Karlsson
Stellan
S
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D008297:Male; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary / Q000628:therapy
D018931:Antineoplastic Agents, Hormonal